MENU
Aim higher

BioGuidePCa

Biomarker Guided Prostate Cancer Management

The BioGuidePCa project is designed to address the European Market demand for a diagnostic test which enables distinguishing between insignificant and significant prostate cancer (PCa). The proposed test detects peptides indicative of PCa by capillary electrophoresis-mass spectrometry (CE-MS). The output of the project will be a non-invasive test, called the “PCa Status Test”, designed to guide the treatment decision-making for patients on active surveillance. This is not a clinical study.
Acronym: 
BioGuidePCa
Project ID: 
11 023
Ranking: 
68
Cut-off: 
6
Start date: 
01-07-2017
Project Duration: 
36months
Project costs: 
1 012 970.00€
Technological Area: 
Biochemistry / Biophysics
Market Area: 
Diagnostic test products and equipment